You just read:

Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus

News provided by

Velocity Pharmaceutical Development

Dec 17, 2014, 08:00 ET